AXSM trade ideas
AXSM - Uptrend! Next target - $35EN : Last Friday, certainly announces a reversal and possibly a return to the top to reach the $ 35. At least four times, the stock has stumbled on its bottom line of mid-term trend andd Friday, it was probably the 5th time.
FR: La journée de vendredi dernier annonce assurément un renversement et possiblement un retour vers le haut pour atteindre le 35$. Au moins à 4 reprises, le titre s'est buté sur sa ligne inférieure de sa tendance moyen terme et vendredi, ce fut surement la 5ème fois.
AXSM Stock Review!Hello everyone! Today I have a short term chart analysis for AXSM. You can see the FULL video analysis by clicking the link below in my signature description!
I have new updated charts, and new video's every day. Please follow me on tradingview, and subscribe to me on youtube!
Leave any questions or comments below, and I will get back to you as soon as possible!
Risk takers: AXSM: Again looks promising to me. Warning: High risk pharmaceutical company. I was early in my last chart in January.
Chart looks more promising to me now. The company is developing non opioid treatments for joint pain, depression, and Alzheimer's disease. Pipeline (see ling below) is in clinical trials. If trials fail often get large drops in price and vice versa. With the opioid crisis IF these meds are helpful would be great potential. Watch for breakup above "1". Have a great weekend.
axsome.com
recent news: seekingalpha.com
AXSM could be the next 4 - 6 bagger biotechstockCash: $41 Million (cash runway into the second quarter of 2019)
Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)
•Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)
•Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)
7 x Phase 3 Programs in Pipeline :
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions in Phase 3 (SPA & Fast Track) ---7M patients in the U.S.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) ---No approved drug = high unmet need. 80,000 new cases per year in the U.S.
AXS-02 Chronic Low Back Pain Associated with Modic Changes in Phase 3 ---1.6M patients in the U.S.
AXS-05 Agitation in patients with Alzheimer’s disease(AD) in Phase 2/3 ---No approved medication = unmet medical need. 2M patients in the U.S.
AXS-05 STRIDE-1 Treatment resistant depression in Phase 3 ---Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.
AXS-06(MoSEIC™ Mx + Eso) Acute and Chronic Pain Phase 3 Ready = 120M NSAID TRx per year in the U.S.
AXS-07 (meloxicam and rizatriptan) for the Treatment of Migraine Phase 3 Ready = Migraine attacks are disabling and affect more than 37 million Americans
